vs
Esperion Therapeutics, Inc.（ESPR）与Clear Secure, Inc.（YOU）财务数据对比。点击上方公司名可切换其他公司
Clear Secure, Inc.的季度营收约是Esperion Therapeutics, Inc.的1.4倍（$240.8M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 16.7%），过去两年Clear Secure, Inc.的营收复合增速更高（16.0% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
Clear Secure, Inc.是美国一家科技企业，主营生物识别旅行证件核验系统，其服务已覆盖部分大型机场与体育场馆。公司成立于2003年，2009年申请破产后停运，2012年重启运营，最终于2021年成功上市。
ESPR vs YOU — 直观对比
营收规模更大
YOU
是对方的1.4倍
$168.4M
营收增速更快
ESPR
高出127.0%
16.7%
两年增速更快
YOU
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $240.8M |
| 净利润 | — | $30.8M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | 22.4% |
| 净利率 | — | 12.8% |
| 营收同比 | 143.7% | 16.7% |
| 净利润同比 | — | -70.2% |
| 每股收益（稀释后） | $0.32 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRYOU
| Q4 25 | $168.4M | $240.8M | ||
| Q3 25 | $87.3M | $229.2M | ||
| Q2 25 | $82.4M | $219.5M | ||
| Q1 25 | $65.0M | $211.4M | ||
| Q4 24 | $69.1M | $206.3M | ||
| Q3 24 | $51.6M | $198.4M | ||
| Q2 24 | $73.8M | $186.7M | ||
| Q1 24 | $137.7M | $179.0M |
净利润ESPRYOU
| Q4 25 | — | $30.8M | ||
| Q3 25 | $-31.3M | $28.3M | ||
| Q2 25 | $-12.7M | $24.7M | ||
| Q1 25 | $-40.5M | $25.4M | ||
| Q4 24 | — | $103.3M | ||
| Q3 24 | $-29.5M | $23.5M | ||
| Q2 24 | $-61.9M | $24.1M | ||
| Q1 24 | $61.0M | $18.8M |
营业利润率ESPRYOU
| Q4 25 | 50.6% | 22.4% | ||
| Q3 25 | -11.4% | 23.0% | ||
| Q2 25 | 8.6% | 19.4% | ||
| Q1 25 | -34.0% | 17.7% | ||
| Q4 24 | -6.4% | 16.5% | ||
| Q3 24 | -31.0% | 17.7% | ||
| Q2 24 | 3.5% | 16.2% | ||
| Q1 24 | 52.5% | 13.2% |
净利率ESPRYOU
| Q4 25 | — | 12.8% | ||
| Q3 25 | -35.9% | 12.3% | ||
| Q2 25 | -15.4% | 11.3% | ||
| Q1 25 | -62.2% | 12.0% | ||
| Q4 24 | — | 50.1% | ||
| Q3 24 | -57.2% | 11.8% | ||
| Q2 24 | -83.9% | 12.9% | ||
| Q1 24 | 44.3% | 10.5% |
每股收益（稀释后）ESPRYOU
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.16 | — | ||
| Q2 25 | $-0.06 | — | ||
| Q1 25 | $-0.21 | — | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.15 | — | ||
| Q2 24 | $-0.33 | — | ||
| Q1 24 | $0.34 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $85.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $177.7M |
| 总资产 | $465.9M | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRYOU
| Q4 25 | $167.9M | $85.7M | ||
| Q3 25 | $92.4M | $75.8M | ||
| Q2 25 | $86.1M | $89.3M | ||
| Q1 25 | $114.6M | $87.6M | ||
| Q4 24 | $144.8M | $66.9M | ||
| Q3 24 | $144.7M | $32.9M | ||
| Q2 24 | $189.3M | $39.1M | ||
| Q1 24 | $226.6M | $64.1M |
股东权益ESPRYOU
| Q4 25 | $-302.0M | $177.7M | ||
| Q3 25 | $-451.4M | $148.6M | ||
| Q2 25 | $-433.5M | $121.3M | ||
| Q1 25 | $-426.2M | $116.7M | ||
| Q4 24 | $-388.7M | $198.4M | ||
| Q3 24 | $-370.2M | $129.0M | ||
| Q2 24 | $-344.2M | $153.5M | ||
| Q1 24 | $-294.3M | $165.9M |
总资产ESPRYOU
| Q4 25 | $465.9M | $1.3B | ||
| Q3 25 | $364.0M | $1.1B | ||
| Q2 25 | $347.1M | $1.2B | ||
| Q1 25 | $324.0M | $1.1B | ||
| Q4 24 | $343.8M | $1.2B | ||
| Q3 24 | $314.1M | $858.6M | ||
| Q2 24 | $352.3M | $982.4M | ||
| Q1 24 | $373.1M | $1.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $198.4M |
| 自由现金流经营现金流 - 资本支出 | — | $187.4M |
| 自由现金流率自由现金流/营收 | — | 77.8% |
| 资本支出强度资本支出/营收 | 0.0% | 4.6% |
| 现金转化率经营现金流/净利润 | — | 6.45× |
| 过去12个月自由现金流最近4个季度 | — | $343.1M |
8季度趋势，按日历期对齐
经营现金流ESPRYOU
| Q4 25 | $45.2M | $198.4M | ||
| Q3 25 | $-4.3M | $-47.3M | ||
| Q2 25 | $-31.4M | $123.0M | ||
| Q1 25 | $-22.6M | $98.3M | ||
| Q4 24 | $-35.0M | $136.6M | ||
| Q3 24 | $-35.3M | $-35.9M | ||
| Q2 24 | $-7.2M | $114.6M | ||
| Q1 24 | $53.8M | $80.3M |
自由现金流ESPRYOU
| Q4 25 | — | $187.4M | ||
| Q3 25 | — | $-53.5M | ||
| Q2 25 | — | $117.9M | ||
| Q1 25 | — | $91.3M | ||
| Q4 24 | — | $133.9M | ||
| Q3 24 | $-35.5M | $-37.9M | ||
| Q2 24 | $-7.3M | $110.1M | ||
| Q1 24 | $53.8M | $77.6M |
自由现金流率ESPRYOU
| Q4 25 | — | 77.8% | ||
| Q3 25 | — | -23.3% | ||
| Q2 25 | — | 53.7% | ||
| Q1 25 | — | 43.2% | ||
| Q4 24 | — | 64.9% | ||
| Q3 24 | -68.7% | -19.1% | ||
| Q2 24 | -9.9% | 59.0% | ||
| Q1 24 | 39.0% | 43.3% |
资本支出强度ESPRYOU
| Q4 25 | 0.0% | 4.6% | ||
| Q3 25 | 0.0% | 2.7% | ||
| Q2 25 | 0.0% | 2.3% | ||
| Q1 25 | 0.0% | 3.4% | ||
| Q4 24 | 0.0% | 1.3% | ||
| Q3 24 | 0.3% | 1.0% | ||
| Q2 24 | 0.1% | 2.4% | ||
| Q1 24 | 0.1% | 1.6% |
现金转化率ESPRYOU
| Q4 25 | — | 6.45× | ||
| Q3 25 | — | -1.67× | ||
| Q2 25 | — | 4.97× | ||
| Q1 25 | — | 3.87× | ||
| Q4 24 | — | 1.32× | ||
| Q3 24 | — | -1.53× | ||
| Q2 24 | — | 4.75× | ||
| Q1 24 | 0.88× | 4.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
YOU
暂无分部数据
